REDEFINE 1 研究评估 CagriSema 2.4 mg 2.4 mg 对早期超重或肥胖成人患者的治疗效果.pdf

1、Blher M et al.Presented at the 33rd European Congress on Obesity(ECO 2026),1215 May 2026,Istanbul,Trkiye.Treatment effect of CagriSema 2.4 mg/2.4 mg in adults with early-onset overweight or obesity in REDEFINE 1Matthias Blher1,Cynthia Karenina Osorto Contreras2,Jason C.G.Halford3,Aaron S.Kelly4,Anan

2、da Kosuvaripalli5,Eva Winning Lehmann2,Kirsi H.Pietilinen6,Dror Dicker71Helmholtz Institute for Metabolic,Obesity,and Vascular Research(HI-MAG)of the Helmholtz Zentrum Mnchen at the University ofLeipzig,Leipzig,Germany;Medical Department III,Clinical Obesity Research,University of Leipzig Medical Ce

3、nter,Leipzig,Germany,2Novo Nordisk A/S,Sborg,Denmark,3School of Psychology,University of Leeds,Leeds,UK;4Department of Pediatrics and Center for Pediatric Obesity Medicine,University of Minnesota Medical School,Minneapolis,Minnesota,USA;5Novo Nordisk Global Business Services,Bangalore,India;6Obesity

4、 Research Unit,Research Program for Clinical and Molecular Metabolism,University of Helsinki,Helsinki,Finland;Healthy Weight Hub,Endocrinology,Abdominal Center,Helsinki University Hospital and University of Helsinki,Helsinki,Finland;7Internal Medicine Department and Obesity Clinic,Hasharon Hospital-

5、Rabin Medical Center,Petah-Tikva,Gray Faculty of Medicine,Tel Aviv University,Tel Aviv,Israel.Blher M et al.Presented at the 33rd European Congress on Obesity(ECO 2026),1215 May 2026,Istanbul,Trkiye.I N C L U D EDI N PO ST ERIntroduction2According to the trial product estimand.1.Juonala M et al.N En

6、gl J Med 2011;365:18761885;2.Kibret KT et al.Obes Rev 2024;25:e13695;3.Garvey WT et al.N Engl J Med 2025;393:635647The aim of this post hoc subgroup analysis of REDEFINE 1 was to compare outcomes with CagriSema according to when participants first developed excess body weightIn the REDEFINE 1 trial(